The University of Tennessee Health Science Center

• M.P.H., Wayne State University College of Medicine, Detroit MI
• Infectious Diseases Pharmacotherapy Fellowship, Wayne State University/Henry Ford Hospital, Detroit MI
• PGY-1 Pharmacy Practice Residency, Henry Ford Hospital, Detroit MI
• Pharm.D., Albany College of Pharmacy, Albany NY

i.  Epidemiology of bacterial and fungal infections

ii. Clinical and economic implications of antimicrobial resistance

iii. Optimization of antimicrobial exposures in select populations

iv. Health-care access in underserved populations

Antimicrobial stewardship, management of multi-drug resistant organisms, invasive fungal infections, Clostridioides difficile-associated diarrhea, antimicrobial optimization in critically ill and/or immunocompromised populations, infections related to injection-drug use

1. Veve, MP, Greene, JB, Williams, AM, Davis, SL, Lu, N, Shnayder, Y, Li, DX, Noureldine, SI, Richmon, JD, Lin, LO, Hanasono, MM, Pipkorn, P, Jackson, RS, Hornig, JD, Light, T, Wax, MK, Yiu, Y, Bekeny, J, Old, M, Hernandez, D, Patel, UA, Ghanem, TA. Multicenter Assessment of Antibiotic Prophylaxis Spectrum on Surgical Infections in Head and Neck Cancer Microvascular Reconstruction. Otolaryngol Head Neck Surg, 194599818756299, 2018.
2. Athans, V, Veve, MP, Davis, SL. Trowels and Tribulations: Review of Antimicrobial-Impregnated Bone Cements in Prosthetic Joint Surgery. Pharmacotherapy, 37 (12), 1565-1577, 2017.
3. Veve, MP, Davis, SL, Williams, AM, McKinnon, JE, Ghanem, TA. Considerations for antibiotic prophylaxis in head and neck cancer surgery. Oral Oncol, 74, 181-187, 2017.
4. Flynt, LK, Veve, MP, Samuel, LP, Tibbetts, RJ. Comparison of Etest to Broth Microdilution for Testing of Susceptibility of Pseudomonas aeruginosa to Ceftolozane-Tazobactam. J Clin Microbiol, 55 (1), 334-335, 2017.
5. Veve, MP, Wagner, JL, Kenney, RM, Grunwald, JL, Davis, SL. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. Int J Antimicrob Agents, 48 (1), 56-60, 2016.
6. Patel, N, Veve, M, Nasiri, M, Bliss, S, McNutt, LA, Lazariu, V, Miller, C. Predicting the probability of experiencing clinically significant drug-drug interactions involving boceprevir-containing hepatitis C therapy among patients coinfected with hepatitis C and HIV. AIDS Patient Care STDS, 28 (10), 513-6, 2014.
7. Patel N, Veve MP, Bliss S, Nasiri M, McNutt LA, Lazariu V, Roman M, Miller CD. Prevalence and predictors of important telaprevir drug interactions among patients co-infected with hepatitis C and human immunodeficiency virus.. J Pharm Technol, 5 (30), 159-67, 2014.
8. Patel, N, Veve, M, Kwon, S, McNutt, LA, Fish, D, Miller, CD. Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation. HIV Med, 14 (8), 463-71, 2013.
9. Patel, N, Abdelsayed, S, Veve, M, Miller, CD. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Ann Pharmacother, 45 (3), 317-24, 2011.